• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·ASKER.ST
Share

Asker Healthcare Group AB Stocks

SEK 76.9Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

SEK 3.18B

SEK 76.9
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

18.08.2025 22:00

Small caps outperforming large caps in Europe since April – can the momentum last?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ASKER.ST is 94 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 16:39

U.S. and Iran could sign an agreement on Sunday to open Hormuz - Bloomberg

12.06.2026 16:12

Shares of luxury brands soar on news of US-Iran agreement

12.06.2026 14:47

Morning in New York: risk appetite returns

12.06.2026 13:58

US-Iran deal includes opening of Hormuz within 30 days - Iran agency

12.06.2026 13:28

The perfect black swan: what the SpaceX IPO will bring to the markets

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026